Myocardial Metabolic Flux in Pulmonary Arterial Hypertension

ConditionPulmonary Arterial Hypertension

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-85

SponsorImperial College London

About this trial

The rationale for this study is that GLP-1 agonist treatment is likely to influence myocardial substrate utilisation, changing the predominant source of metabolic energy within the heart to a more energetically efficient form. This is represented by a surrogate for improved mitochondrial efficiency with reduction in myocardial lactate levels (produced by inefficient myocardial glycolysis, prevalent in the ventricles of patients with pulmonary hypertension), which can be measured by 31P-magnetic resonance spectroscopy (31P-MRS).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

• 1. Pregnancy

2. Myocardial infarction within the previous 3 months

3. Contraindications to MRI: Pacemakers, metallic implants, or severe claustrophobia.

4. Severe renal impairment: eGFR < 15ml/min/1.73m.

Trial design

Design model

Single group

Treatments tested in this trial

GLP-1 agonist
Drug
Semaglutide

Treatment groups

32 Participants

are divided into 1 treatment group

Group A: Standard of careActive comparator 1 intervention

Trial outcomes

Primary outcomes

Change in the phosphocreatine-to-adenosine triphosphate (31PCr/ATP) ratio between baseline and follow up in response to treatment with GLP-1 agonist

Time frame

12 weeks

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Imperial College London

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: